Comparison of methods of evaluating nephrotoxicity of cis-platinum

Brian R. Jones, Ravi B. Bhalla, Jiri Mladek, Ronald N. Kaleya, Richard J. Gralla, Nancy W. Alcock, Morton K. Schwartz, Charles W. Young, Marcus M. Reidenberg

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

The urinary, excretion of leucine aminopeptidase (LAP), N-acetyl-β-glucosaminidase (NAG), and β2-microglobulin was measured in 12 cancer patients receiving cis-platinum to evaluate the sensitivity, of these indices for renal tubular damage. NAG and LAP excretion rose markedly in all patients, and β2-microglobulin rose in 11. Seven of the 9 patients who had received cis-platinum 6 wk before the study had prestudy dose elevations of one or more of these indices. We conclude that these urinary proteins are sensitive indicators of proximal renal tubular injury and may provide greater sensitivity for comparison of the nephrotoxic potential of future platinum analogs or for assessing the efficacy, of regimens designed to protect the kidney from platinum nephrotoxicity than other measurements. The persistence of high excretion values for these indices 6 wk after a dose demonstrates the persistent renal injury, by cis-platinum.

Original languageEnglish (US)
Pages (from-to)557-562
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume27
Issue number4
StatePublished - Apr 1980
Externally publishedYes

Fingerprint

Cisplatin
Leucyl Aminopeptidase
Kidney
Hexosaminidases
Platinum
CD13 Antigens
Wounds and Injuries
Neoplasms
Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Jones, B. R., Bhalla, R. B., Mladek, J., Kaleya, R. N., Gralla, R. J., Alcock, N. W., ... Reidenberg, M. M. (1980). Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clinical Pharmacology and Therapeutics, 27(4), 557-562.

Comparison of methods of evaluating nephrotoxicity of cis-platinum. / Jones, Brian R.; Bhalla, Ravi B.; Mladek, Jiri; Kaleya, Ronald N.; Gralla, Richard J.; Alcock, Nancy W.; Schwartz, Morton K.; Young, Charles W.; Reidenberg, Marcus M.

In: Clinical Pharmacology and Therapeutics, Vol. 27, No. 4, 04.1980, p. 557-562.

Research output: Contribution to journalArticle

Jones, BR, Bhalla, RB, Mladek, J, Kaleya, RN, Gralla, RJ, Alcock, NW, Schwartz, MK, Young, CW & Reidenberg, MM 1980, 'Comparison of methods of evaluating nephrotoxicity of cis-platinum', Clinical Pharmacology and Therapeutics, vol. 27, no. 4, pp. 557-562.
Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alcock NW et al. Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clinical Pharmacology and Therapeutics. 1980 Apr;27(4):557-562.
Jones, Brian R. ; Bhalla, Ravi B. ; Mladek, Jiri ; Kaleya, Ronald N. ; Gralla, Richard J. ; Alcock, Nancy W. ; Schwartz, Morton K. ; Young, Charles W. ; Reidenberg, Marcus M. / Comparison of methods of evaluating nephrotoxicity of cis-platinum. In: Clinical Pharmacology and Therapeutics. 1980 ; Vol. 27, No. 4. pp. 557-562.
@article{12730092a0ed43b986c1ec671e724696,
title = "Comparison of methods of evaluating nephrotoxicity of cis-platinum",
abstract = "The urinary, excretion of leucine aminopeptidase (LAP), N-acetyl-β-glucosaminidase (NAG), and β2-microglobulin was measured in 12 cancer patients receiving cis-platinum to evaluate the sensitivity, of these indices for renal tubular damage. NAG and LAP excretion rose markedly in all patients, and β2-microglobulin rose in 11. Seven of the 9 patients who had received cis-platinum 6 wk before the study had prestudy dose elevations of one or more of these indices. We conclude that these urinary proteins are sensitive indicators of proximal renal tubular injury and may provide greater sensitivity for comparison of the nephrotoxic potential of future platinum analogs or for assessing the efficacy, of regimens designed to protect the kidney from platinum nephrotoxicity than other measurements. The persistence of high excretion values for these indices 6 wk after a dose demonstrates the persistent renal injury, by cis-platinum.",
author = "Jones, {Brian R.} and Bhalla, {Ravi B.} and Jiri Mladek and Kaleya, {Ronald N.} and Gralla, {Richard J.} and Alcock, {Nancy W.} and Schwartz, {Morton K.} and Young, {Charles W.} and Reidenberg, {Marcus M.}",
year = "1980",
month = "4",
language = "English (US)",
volume = "27",
pages = "557--562",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Comparison of methods of evaluating nephrotoxicity of cis-platinum

AU - Jones, Brian R.

AU - Bhalla, Ravi B.

AU - Mladek, Jiri

AU - Kaleya, Ronald N.

AU - Gralla, Richard J.

AU - Alcock, Nancy W.

AU - Schwartz, Morton K.

AU - Young, Charles W.

AU - Reidenberg, Marcus M.

PY - 1980/4

Y1 - 1980/4

N2 - The urinary, excretion of leucine aminopeptidase (LAP), N-acetyl-β-glucosaminidase (NAG), and β2-microglobulin was measured in 12 cancer patients receiving cis-platinum to evaluate the sensitivity, of these indices for renal tubular damage. NAG and LAP excretion rose markedly in all patients, and β2-microglobulin rose in 11. Seven of the 9 patients who had received cis-platinum 6 wk before the study had prestudy dose elevations of one or more of these indices. We conclude that these urinary proteins are sensitive indicators of proximal renal tubular injury and may provide greater sensitivity for comparison of the nephrotoxic potential of future platinum analogs or for assessing the efficacy, of regimens designed to protect the kidney from platinum nephrotoxicity than other measurements. The persistence of high excretion values for these indices 6 wk after a dose demonstrates the persistent renal injury, by cis-platinum.

AB - The urinary, excretion of leucine aminopeptidase (LAP), N-acetyl-β-glucosaminidase (NAG), and β2-microglobulin was measured in 12 cancer patients receiving cis-platinum to evaluate the sensitivity, of these indices for renal tubular damage. NAG and LAP excretion rose markedly in all patients, and β2-microglobulin rose in 11. Seven of the 9 patients who had received cis-platinum 6 wk before the study had prestudy dose elevations of one or more of these indices. We conclude that these urinary proteins are sensitive indicators of proximal renal tubular injury and may provide greater sensitivity for comparison of the nephrotoxic potential of future platinum analogs or for assessing the efficacy, of regimens designed to protect the kidney from platinum nephrotoxicity than other measurements. The persistence of high excretion values for these indices 6 wk after a dose demonstrates the persistent renal injury, by cis-platinum.

UR - http://www.scopus.com/inward/record.url?scp=0018887097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018887097&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 557

EP - 562

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -